So What's Going On With Ensysce Biosciences Shares Shooting Higher Monday?

Ensysce Biosciences Inc ENSC shares are trading higher by 5.12% to $2.26 Monday morning after the company announced that it has successfully completed the clinical portion of study PF614-MPAR-101 Part A.

What Else?

Per Ensysce, MPAR^TM (Multi-Pill Abuse Resistance) is designed to prevent drug overdose by inhibiting the activation and release of opioid when more than prescribed doses are taken. PF614 is a TAAP^TM (Trypsin Activated Abuse Protection) prodrug of oxycodone designed to reduce abuse of this opioid pain medication.

Dr. Lynn Kirkpatrick, CEO of Ensysce, commented, "Overdose with opioids is a societal crisis. Hundreds of Americans die each day due to deliberate and accidental overdoses. PF614-MPAR is designed to provide two layers of safety, one to reduce casual abuse and the second to prevent accidental overdose. We are looking forward to reporting the final data from this part of the trial and expect to do so by the end of this month."

According to data from Benzinga Pro, ENSC has a 52-week high of $140.00 and a 52-week low of $1.90.